Dennis Purcell

Published on February 10, 2015 at 9:38 pm by Insider Monkey Staff in

Page 1 of 13

Loxo Oncology Inc. (NASDAQ:LOXO): Dennis Purcell’s Aisling Capital III LP filed an amended 13D.

You can check out Aisling Capital’s latest holdings and filings here.

Please follow Aisling Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Aisling Capital or update its stock holdings.

Dennis Purcell

Aisling Capital

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Aisling Capital III	3,688,920	0	3,688,920	0	3,688,920	12.3%
Aisling Capital Partners III	3,688,920	0	3,688,920	0	3,688,920	12.3%
Aisling Capital Partners III	3,688,920	0	3,688,920	0	3,688,920	12.3%
Steven Elms	0	3,688,920	0	3,688,920	3,688,920	12.3%
Dennis Purcell	0	3,688,920	0	3,688,920	3,688,920	12.3%
Andrew Schiff	0	3,688,920	0	3,688,920	3,688,920	12.3%

Page 1 of 13 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

RULE 13d-2(a)

(Amendment No. 2)*

Loxo Oncology, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

548862101

(CUSIP Number)

Robert Wenzel

Aisling Capital

888 Seventh Avenue, 12th Floor

New York, NY 10106

(212) 651-6380

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

November 22, 2017

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box . ☒

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Loxo Oncology Inc. (NASDAQ:LOXO)Follow Loxo Oncology Inc. (NASDAQ:LOXO)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.